An interventional study of For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: in Urothelial Carcinoma, Renal Cancer and Prostate Adenocarcinoma, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carcinoma, Transitional Cell with a site in France — 16 open to participants now, 28 under way, 7 of them phase 3. Carcinoma, Transitional Cell · France.
Among the 71 studies in Carcinoma, Transitional Cell with a site in France, this one is the 15th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2025, is the only one with no phase, reaches primary completion later than 24 of the 27 other live ones, and was the 64th registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →16 of the 71 studies in Carcinoma, Transitional Cell with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 13 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in France, United States, Brazil and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in France, United States, Australia and 16 more countries
Ages 18+
Daiichi Sankyo · Sites in France, United States, Austria and 4 more countries
Ages 18+
Alentis Therapeutics AG · Sites in France, United States, Hong Kong and 5 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 14
First in 2002; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 50 across 500 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 181 across the 62 interventional studies, 389 across the 9 observational. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 71 have an industry lead sponsor. The 10 most frequent:
Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.
Institut Claudius Regaud has 1 study filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
7 of the studies in Carcinoma, Transitional Cell with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
| NCT06632951AbbVieStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 71 studies in Carcinoma, Transitional Cell with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.
Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.
450 patients will be enrolled in total.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients: * Cohort 1 : urothelial carcinoma * Cohort 2 : renal carcinoma * Cohort 3 : prostate adenocarcinoma * Cohort 4 : upper aerodigestive tract carcinoma * Cohort 5 : cervical carcinoma * Cohort 6 : adenocarcinoma of endometrium * Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients: * Cohort 7 : cutaneous melanoma * Cohort 8 : soft tissue sarcoma * Cohort 9 : seminomatous and nonseminomatous germ cell tumors
Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor)
It is defined as the ratio of number of patients for whom DP cells were detected (by at least 1 of the 2 techniques) by the total number of patients.
Time frame: 1 year after the Last Patient Last Visit
Rate of patients presenting blood circulating DP cells detected by each method of analysis (Flow Cytometry and CellSearch® or Parsortix® according to the tumor type)
It is defined as the ratio of the number of patients presenting DP cells (detected by the concerned technique) by the total number of patients
Time frame: 1 year after the Last Patient Last Visit
Started Jul 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.
Of 29 interventional studies with no phase under Carcinoma, Transitional Cell, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 23. This study's planned 48 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Transitional Cell →